Endostatin gene therapy - Valentis

Drug Profile

Endostatin gene therapy - Valentis

Latest Information Update: 15 Jan 2002

Price : $50

At a glance

  • Originator Valentis
  • Developer Urigen Pharmaceuticals
  • Class Antineoplastics; Eye disorder therapies; Gene therapies
  • Mechanism of Action Angiogenesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Suspended Cancer

Most Recent Events

  • 15 Jan 2002 Suspended - Preclinical for Cancer in USA (unspecified route)
  • 22 Jun 1999 Megabios has merged with GeneMedicine to form Valentis
  • 22 Apr 1999 Preclinical development for Cancer in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top